Author
By Christopher Robertson As many readers of this blog know, the FDA requires that, prior to entering the market, companies prove safety and efficacy for each intended use of their products, but physicians are then free to…
By Christopher Robertson “I believe and I look forward to working with you to make certain that every single American has access to the highest-quality care and coverage that is possible. … [W]e believe it’s…
By Christopher Robertson With 148,000 members, the American College of Physicians (ACP) is the largest medical-speciality organization. This summer, its board released a new report on the growing financial burdens faced by patients who enjoy health insurance but…
By Christopher Robertson Whether it is Ebola, H1N1, the season flu, or the next nasty bug that we cannot yet even imagine, if we wanted to efficiently spread the disease, one could not do much…
By Chris Robertson July has been a busy month for those following the controversy around off-label promotion of drugs and devices. As many on this blog know, federal law requires that prior to marketing any…
By Christopher Robertson As part of the Regulatory Science series at University of Arizona: Health Law and Health Policy: A Frictional Account William M. Sage, MD, JD, University of Texas Today 12/2 — Noon (AZ…
By Christopher Robertson This week, my colleague Derek Bambauer will speak as part of the Regulatory Science series at the University of Arizona. Free CLE attendance form and readings are available. Tune in at 12:00pm (Pacific)…
Bill of Health contributor Christopher T. Robertson has a new Op-Ed out in the New England Journal of Medicine: As one of only two countries that permit direct-to-consumer advertising (DTCA) of pharmaceuticals, the United States tasks…
By Christopher Robertson Co-blogged with University of Arizona Fellow, Jonathan Loe Breathlessly, many news outlets reported yesterday that Kim Kardashian West was in trouble with the FDA for misleading social media advertising of the drug…
By Christopher Robertson Over at the Health Affairs blog, I have a new post on industry funding of science, the power of disclosure, and alternative funding models for biomedical science. Check it out.
